70-year old patient, Mrs. Darlene Bossolla, was diagnosed with inoperable pancreatic cancer last year. Now, part of the TIGeR-PaC clinical trial at UPMC with Dr. Paula Novelli, Mrs. Bossola is reporting her levels to be down and she is feeling great and that she believes this new procedure should be available to everyone.
Based on results of early studies highlighted by this patient’s and other patients’ experiences, RenovoRx initiated and is currently enrolling Stage 3 pancreatic cancer patients in the TIGeR-PaC clinical trial to further test this promising new procedure for pancreatic cancer patients.
RenovoRx Inc. today announces that its Board of Directors has appointed Shaun R. Bagai as Chief Executive Officer and member of the Board of Directors effective June 16, 2014.
RenovoRx’s Board Member Dr. Laurence (Larry) J. Marton, MD is a leading expert with extensive experience in the fields of drug development, with a focus on treating human diseases related to cell growth including cancer.
RenovoRx today announces that it has been chosen as a winner of the 2013 TiE50 Awards, a highly influential list of the most enterprising startup companies across five verticals: Internet, Software, Mobile, Life Sciences, and Energy.
RenovoRx is featured in the February 2013 issue of START-UP, an Elsevier Business Intelligence publication of in-depth profiles of leading-edge companies and technologies.
RenovoRx has been selected for the 10th Annual BayBio Entrepreneur and Investor Roundtables to be held on February 14, 2013 in San Francisco.
RenovoRx is thrilled to announce that Klaus W. Hambuechen, Laurence Marton, MD, and Una Ryan, PhD, have joined Marta Gaia Zanchi, PhD, CEO and Dr. Ramtin Agah, MD, CMO on the Company’s Board of Directors.
* Individual results may vary.
